Increased levels of soluble receptor for advanced glycation end products (sRAGE) and high mobility group box 1 (HMGB1) are associated with death in patients with acute respiratory distress syndrome

Clinical Biochemistry

Volumn 44, Issue 8-9, 2011, Pages 601-604

  Nakamura, Tsukasa ^a   Sato, Eiichi ^a   Fujiwara, Nobuharu ^a   Kawagoe, Yasuhiro ^a   Maeda, Sayaka ^b   Yamagishi, Sho ichi ^b  

^a Shinmatsudo Central General Hospital   (Japan)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

ARDS; HMGB1; sRAGE

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 6;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGE; AGED; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DEATH; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GENETIC ASSOCIATION; HUMAN; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEX DIFFERENCE;

AGED; FEMALE; HMGB1 PROTEIN; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; MUCIN-1; RECEPTORS, IMMUNOLOGIC; RESPIRATORY DISTRESS SYNDROME, ADULT;

EID: 79955788043     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2010.12.014     Document Type: Article

References (39)

1. Dos Santos C.C. Advances in mechanisms of repair and remodelling in acute lung injury. Intensive Care Med. 2008, 34:619-630.
2. Raghavendran K., Pryhuber G.S., Chess P.R., Davidson B.A., Knight P.R., Notter R.H. Pharmacotherapy of acute lung injury and acute respiratory distress syndrome. Curr. Med. Chem. 2008, 15:1911-1924.
3. Tomashefski J.F. Pulmonary pathology of acute respiratory distress syndrome. Clin. Chest Med. 2000, 21:435-466.
4. Dechert R.E. The pathophysiology of acute respiratory distress syndrome. Respir. Care Clin. N. Am. 2003, 9:283-296.
5. Schwarz M.A. Acute lung injury: cellular mechanisms and derangements. Paediatr. Respir. Rev. 2001, 2:3-9.
6. Yamagishi S., Nakamura K., Matsui T. Regulation of advanced glycation end product (AGE)-receptor (RAGE) system by PPAR-gamma agonists and its implication in cardiovascular disease. Pharmacol. Res. 2009, 60:174-178.
7. Creagh-Brown B.C., Quinlan G.J., Evans T.W., Burke-Gaffney A. The RAGE axis in systemic inflammation, acute lung injury and myocardial dysfunction: an important therapeutic target?. Intensive Care Med. 2010, 36:1644-1656.
8. Sims G.P., Rowe D.C., Rietdijk S.T., Herbst R., Coyle A.J. HMGB1 and RAGE in inflammation and cancer. Annu. Rev. Immunol. 2010, 28:367-388.
9. Alexiou P., Chatzopoulou M., Pegklidou K., Demopoulos V.J. RAGE: a multi-ligand receptor unveiling novel insights in health and disease. Curr. Med. Chem. 2010, 21:2232-2252.
10. Schmidt A.M., Yan S.D., Yan S.F., Stern D.M. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J. Clin. Invest. 2001, 108:949-955.
11. Fiuza C., Bustin M., Talwar S., et al. Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 2003, 101:2652-2660.
12. Huttunen H.J., Rauvala H. Amphoterin as an extracellular regulator of cell motility: from discovery to disease. J. Intern. Med. 2004, 255:351-366.
13. Abraham E., Arcaroli J., Carmody A., Wang H., Tracey K.J. Cutting edge: HMGB1 as a mediator of acute lung inflammation. J. Immunol. 2000, 165:2950-2954.
14. Gibot S., Massin F., Cravoisy A., et al. High-mobility group box 1 protein plasma concentrations during septic shock. Intensive Care Med. 2007, 33:1347-1353.
15. Gaini S., Pedersen S.S., Koldkjaer O.G., Pedersen C., Moller H.J. High mobility group box-1 protein in patients with suspected community-acquired infections and sepsis: a prospective study. Crit. Care 2007, 11:R32.
16. Zhang H., Tasaka S., Shiraishi Y., et al. Role of soluble receptor for advanced glycation end products on exdotoxin-induced lung injury. Am. J. Respir. Crit. Care Med. 2008, 178:356-362.
17. Yan S.F., D'Agati V., Schmidt A.M., Ramasamy R. Receptor for Advanced Glycation Endproducts (RAGE): a formidable force in the pathogenesis of the cardiovascular complications of diabetes & aging. Curr. Mol. Med. 2007, 7:699-710.
18. Yamagishi S., Matsui T. Soluble form of a receptor for advanced glycation end products (sRAGE) as a biomarker. Front. Biosci. 2010, 2:1184-1195.
19. Moser B., Hudson B.I., Schmidt A.M. Soluble RAGE: a hot new biomarker for the hot joint?. Arthritis Res. Ther. 2005, 7:142-144.
20. Uchida T., Shirasawa M., Ware L.B., et al. Receptor for advanced glycation end-products is a marker of type I cell injury in acute lung injury. Am. J. Respir. Crit. Care Med. 2006, 173:1008-1015.
21. Su X., Looney M.R., Gupta N., Matthay M.A. Receptor for advanced glycation end-products (RAGE) is an indicator of direct lung injury in models of experimental lung injury. Am. J. Physiol. Lung Cell. Mol. Physiol. 2009, 297:L1-L5.
22. Bernard G.R., Artigas A., Brigham K.L., et al. The American-European consensus conference on ARDS: definitions, mechanisms, relevant outcomes and clinical trial coordination. Am. J. Respir. Crit. Care Med. 1994, 149:818-824.
23. Knaus W., Draper E., Wagner D., Zimmerman J. APACHE II: a severity of disease classification system. Crit. Care Med. 1985, 13:818-829.
24. Murray J.F., Matthay M.A., Luce J.M., Flick M.R. An expanded definition of the adult respiratory distress syndrome. Am. Rev. Respir. Dis. 1988, 138:720-723.
25. Ishizaka A., Matsuda T., Albertine K.H., et al. Elevation of KL-6, a lung epithelial cell marker, in plasma and epithelial lining fluid in acute respiratory distress syndrome. Am. J. Physiol. Lung Cell. Mol. Physiol. 2004, 286:L1088-L1094.
26. Yamada S., Yakabe K., Ishii J., Imaizumi H., Maruyama I. New high mobility group box-1 assay system. Clin. Chin. Acta 2006, 372:173-178.
27. Nakamura K., Sato E., Fujiwara N., et al. Circulating levels of advanced glycation end products (AGE) and interleukin-6 (IL-6) are independent determinants of serum asymmetric dimethylarginine (ADMA) levels in patients with septic shock. Pharmacol. Res. 2009, 60:515-518.
28. Nakamura K., Yamagishi S., Adachi H., et al. Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein-1 (MCP-1) levels in patients with type 2 diabetes. Diabetes Metab. Res. Rev. 2008, 24:109-114.
29. Calfee C.S., Ware L.B., Eisner M.D., et al. NHLBI ARDS Network, plasma receptor for advanced glycation end products and clinical outcomes in acute lung injury. Thorax 2008, 63:1083-1089.
30. The acute respiratory distress syndrome network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N. Engl. J. Med. 2000, 342:1301-1308.
31. Raucci A., Cugusi S., Antonelli A., et al. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J. 2008, 22:3716-3727.
32. Nakamura K., Yamagishi S., Nakamura Y., et al. Telmisartan inhibits expression of a receptor for advanced glycation end products (RAGE) in angiotensin-II-exposed endothelial cells and decreases serum levels of soluble RAGE in patients with essential hypertension. Microvasc. Res. 2005, 70:137-141.
33. Tan K.C., Shiu S.W., Chow W.S., Leng L., Bucala R., Betteridge D.J. Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes. Diabetologia 2006, 49:2756-2762.
34. Humpert P.M., Djuric Z., Kopf S., et al. Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes. Cardiovasc. Diabetol. 2007, 6:9.
35. Nakamura K., Yamagishi S., Adachi H., et al. Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes. Microvasc. Res. 2008, 76:52-56.
36. Nakamura K., Yamagishi S., Adachi H., et al. Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes. Mol. Med. 2007, 13:185-189.
37. Wang H., Bloom O., Zhang M., et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999, 285:248-251.
38. Bopp C., Bierhaus A., Hofer S., et al. Bench-to-bedside review: the inflammation-perpetuating pattern-recognition receptor RAGE as a therapeutic target in sepsis. Crit. Care 2008, 12:201.
39. Bopp C., Hofer S., Weitz J., et al. sRAGE is elevated in septic patients and associated with patients outcome. J. Surg. Res. 2008, 147:79-83.